Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Miren Zamacona"'
Publikováno v:
The Journal of Clinical Pharmacology. 63:435-444
Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhibits CD40 ligand (CD40L) and is currently undergoing phase 3 trials for the treatment of SLE. To desc
Autor:
Gary Burgess, Malcolm Boyce, Margaret Jones, Lars Larsson, Mark J. Main, Frazer Morgan, Peter Phillips, Alison Scrimgeour, Foteini Strimenopoulou, Pavan Vajjah, Miren Zamacona, Roger Palframan
Publikováno v:
EBioMedicine, Vol 35, Iss , Pp 67-75 (2018)
Background: Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-
Externí odkaz:
https://doaj.org/article/4112209b44a549208dede8f273b97447
Autor:
Peter Colman, Chris Chamberlain, Geoffrey I Johnston, Falk Hiepe, Ann Ranger, C. Stach, Thomas Dörner, Linda C. Burkly, Murray B. Urowitz, Miren Zamacona, Christian Otoul
Publikováno v:
Annals of the Rheumatic Diseases. 76:1837-1844
ObjectivesSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with diffuse immune cell dysfunction. CD40–CD40 ligand (CD40L) interaction activates B cells, antigen-presenting cells and platelets. CD40L blockade might
Autor:
Alastair D. G. Lawson, Ralph Adams, Joanne E. Compson, Tim Kopotsha, Michael Airey, Hanna Hailu, David Paul Humphreys, Oliver Zaccheo, Kaushik Sarkar, Mark Jairaj, Wild Gavin Barry, Andrew M. Ventom, Sarah L. Dugdale, Louis Christodoulou, Emma Dave, Sarah Malcolm, Diane Marshall, Alison Turner, Bruce Carrington, James T. Heads, Miren Zamacona, Sam Philip Heywood
Publikováno v:
mAbs
An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of
Autor:
Frazer Giles Morgan, Mark Jonathan Main, Peter Phillips, Pavan Vajjah, Roger Palframan, Malcolm Boyce, Foteini Strimenopoulou, Miren Zamacona, Lars Larsson, Margaret Jones, Gary Burgess, Alison Scrimgeour
Publikováno v:
EBioMedicine. 35
Background Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-p
Publikováno v:
Basicclinical pharmacologytoxicology. 106(3)
Animal-to-man extrapolation and therapeutic dose prediction are illustrated with two molecules designed to treat epilepsy. Synaptic vesicle protein 2A (SV2A) is the primary molecular target for their anticonvulsive effect, but additional mechanisms m
Publikováno v:
Journal of Clinical Pharmacology; Apr2023, Vol. 63 Issue 4, p435-444, 10p
Autor:
Chamberlain, Chris, Colman, Peter J., Ranger, Ann M., Burkly, Linda C., Johnston, Geoffrey I., Otoul, Christian, Stach, Christian, Zamacona, Miren, Dörner, Thomas, Urowitz, Murray, Hiepe, Falk
Publikováno v:
Annals of the Rheumatic Diseases; Nov2017, Vol. 76 Issue 11, p1837-1844, 8p, 1 Diagram, 2 Charts, 3 Graphs
Autor:
Davé, Emma, Adams, Ralph, Zaccheo, Oliver, Carrington, Bruce, Compson, Joanne E., Dugdale, Sarah, Airey, Michael, Malcolm, Sarah, Hailu, Hanna, Wild, Gavin, Turner, Alison, Heads, James, Sarkar, Kaushik, Ventom, Andrew, Marshall, Diane, Jairaj, Mark, Kopotsha, Tim, Christodoulou, Louis, Zamacona, Miren, Lawson, Alastair D.
Publikováno v:
mAbs; Oct2016, Vol. 8 Issue 7, p1319-1335, 17p